Alnylam Pharmaceuticals (NASDAQ: ALNY) Reports Q2 2026 Earnings Thursday July 30 With Amvuttra (Vutrisiran) Quarterly Revenue Crossing $1 Billion for the First Time at $1.012 Billion (Approximately $4 Billion Annualized Run Rate ~15 Months After the ATTR-CM Launch); Total Q2 Revenue of $1.29 Billion (+67% Year-Over-Year) Fell Short of the $1.31 Billion Analyst Consensus and Full-Year 2026 TTR Product Sales Guidance Revised Down to $4.2-4.5 Billion on Normalized Second-Line Volume; Second-Half 2026 Readouts Expected From ALN-6400 (Hereditary Hemorrhagic Telangiectasia) and ALN-2232 (Obesity/Weight Management)
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q2 2026 earnings Thursday July 30, 2026 before market open. Amvuttra (vutrisiran) quarterly revenue crossed $1 billion for the first time at $1.012 billion (approximately a $4 billion annualized run rate approximately 15 months after the ATTR-CM launch). Total Q2 revenue reached $1.29 billion (+67% year-over-year) but fell short of the $1.31 billion analyst consensus. Net product revenues were $1.17 billion (+74% YoY) versus the $1.22 billion estimate. GAAP diluted EPS was $1.21 versus the $1.49 estimate. Full-year 2026 TTR product sales guidance was revised down to $4.2-4.5 billion to reflect normalized second-line volume after the initial pent-up demand from patients waiting for a new therapy. Pipeline updates: Alnylam expects to announce clinical data from Phase 1 and Phase 2 trials of ALN-6400 in healthy volunteers and patients with hereditary hemorrhagic telangiectasia (HHT) in second-half 2026, plus results from the Phase 1 trial of ALN-2232 (Alnylam's second obesity-track siRNA) in the same second-half window. The ALN-6222 obesity siRNA Phase 1 trial (NCT07624071) opened enrollment in July 2026 with a first-in-human single-ascending-dose design in adults with BMI 30-40 kg/m² at a single site in Mount Royal, Canada through December 2027.